ZYRTEC-D

This brand name is authorized in Cyprus, Ecuador, Hong Kong, Singapore

Active ingredients

The drug ZYRTEC-D contains a combination of these active pharmaceutical ingredients (APIs):

1 Cetirizine UNII YO7261ME24 - CETIRIZINE

Cetirizine, a human metabolite of hydroxyzine, is a potent and selective antagonist of peripheral H1-receptors. In vitro receptor binding studies have shown no measurable affinity for other than Η1-receptors. Read about Cetirizine

2 Pseudoephedrine UNII 7CUC9DDI9F - PSEUDOEPHEDRINE

Pseudoephedrine is a sympathomimetic agent with direct and indirect effects on adrenergic receptors. It has alpha and beta adrenergic activity and some stimulant effect on the central nervous system. The sympathomimetic effect of pseudoephedrine produces vasoconstriction which in turn relieves nasal congestion. Read about Pseudoephedrine

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ZYRTEC-D Prolonged release tablet	Marketing Authorisation Holder	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
R01BA52	Pseudoephedrine, combinations	R Respiratory system → R01 Nasal preparations → R01B Nasal decongestants for systemic use → R01BA Sympathomimetics
Discover more medicines within R01BA52

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 2393-MEE-0816
Country: HK	Department of Health Drug Office	Identifier(s): 53111
Country: SG	Health Sciences Authority	Identifier(s): 13139P